Streamex Corp. (STEX) Stock Price & Analysis
Streamex Corp. (STEX) fell 3.66% to USD 0.74 as of July 25, 2026 at 14:21 UTC, according to Nexqual real-time market data.
STEX last closed at USD 0.76; the session ranged USD 0.72–0.79 on volume of 839,160 shares. Market capitalization is $157.02M, with a 52-week range of USD 0.7–7.44 (NCM). Source: Nexqual, July 25, 2026 at 14:21 UTC.
Key Statistics (as of July 25, 2026 at 14:21 UTC)
| Price | USD 0.74 |
|---|---|
| Change | ▼ 3.66% (down) |
| Previous Close | USD 0.76 |
| Open | USD 0.77 |
| Day Range | USD 0.72 – 0.79 |
| 52-Week Range | USD 0.7 – 7.44 |
| Volume | 839,160 shares |
| Market Cap | $157.02M |
| Exchange | NCM |
Technical Analysis (STEX)
Nexqual's technical model rates STEX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 14:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.21 (neutral) |
| vs SMA50 | Below (USD 0.99) |
| MACD | -0.06 (negative) |
Analyst Ratings (STEX)
Wall Street analysts rate STEX "None" based on 1 analysts, with a mean price target of USD 8 (range USD 8–8), per Nexqual as of July 25, 2026 at 14:21 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 8 |
| High Target | USD 8 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (STEX)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.02 |
| Revenue Estimate | $300,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.27 vs est -0.03 ▼ miss |
| 2025-12-31 | USD -0.45 vs est -0.05 ▼ miss |
| 2025-06-30 | USD -0.74 vs est -0.04 ▼ miss |
Source: Nexqual, July 25, 2026 at 14:21 UTC.
Financials & Fundamentals (STEX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -625.17% |
| Current Ratio | 13.9 |
| Total Cash | $30.63M |
| Total Debt | $0 |
| Free Cash Flow | $12.37M |
Source: Nexqual, July 25, 2026 at 14:21 UTC.
Financial Health Score (STEX)
Nexqual rates Streamex Corp.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 14:21 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $31M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$20M |
| Efficiency | Critical — ROE -625%, ROA -71.0% |
Ownership (STEX)
| Insider Ownership | +24.57% |
|---|---|
| Institutional Ownership | +24.64% |
| Shares Outstanding | 104.27M |
| Float | 75.48M |
| Short % of Float | +8.33% |
Source: Nexqual, July 25, 2026 at 14:21 UTC.
Leadership (STEX)
Streamex Corp. is led by Karl Henry McPhie (age 24), Co-Founder, CEO & Director, per Nexqual as of July 25, 2026 at 14:21 UTC.
| Co-Founder, CEO & Director | Karl Henry McPhie (age 24) |
|---|---|
| Co-Founder & Interim Executive Chairman | Morgan Lekstrom (age 39) |
| CFO and Principal Accounting & Financial Officer | Christine M. Plummer (age 53) |
| Senior Vice President of Investor Relations | Adele Carey |
Major Backers & Investors (STEX)
Notable institutional backers of Streamex Corp. include Legacy Wealth Managment, LLC/ID, Yorkville Advisors Global, LP, Fidelity, according to Nexqual as of July 25, 2026 at 14:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Legacy Wealth Managment, LLC/ID | 43.01% |
| Yorkville Advisors Global, LP | 22.95% |
| Fidelity | 4.88% |
| Millennium Management | 4.43% |
| Susquehanna International Group, LLP | 4.05% |
| Shay Capital LLC | 3.44% |
| Marshall Wace LLP | 3.29% |
| VALIC Co I-Small Cap Special Values Fund | 0.3% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.71% |
| Geode Capital | 5.62% |
Source: Nexqual, July 25, 2026 at 14:21 UTC.
From Streamex Corp.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Streamex is not designed to take proprietary commodity price exposure and is structured to operate with limited direct exposure to underlying commodity price volatility.   Business Model and Platform Scope   Streamex's business model is focused on the development and operation of the Streamex Platform, a software based infrastructure solution that supports the digital representation and administration of tokenized RWA products.
- The Company's former established technology team with external partners and collaborators were joined to advance the research and development of an artificial intelligence ("AI") medical device platform.       Intellectual Property   Patents   Our success with our medical device technology depends in large part on our ability to establish and maintain the proprietary nature of our technology.
- These risks could adversely affect trust in our platform and the perceived integrity of our token offerings.   Tokenholders may not have perfected rights to underlying gold and may be treated as unsecured creditors in an insolvency scenario.   Depending on product structure, tokenholders may not have direct legal title to specific bullion bars or a perfected security interest in underlying assets.
- In addition, we face competition from traditional gold investment products such as exchange-traded funds (ETFs), futures contracts, and bullion dealers, which are already widely accepted by retail and institutional investors.   If we are unable to successfully differentiate our platform, build user trust, secure high-quality counterparties, or scale liquidity in our tokenized offerings, we may not be able to compete effectively.
Partnerships
- Each GLDY Token corresponds to one troy ounce of gold held by the SPV, with yield features generated through gold leasing activities administered through a Tokenized Yield Partnership Agreement (the "MM Agreement"), by and between the Company and Monetary Metals & Co., a Delaware corporation ("Monetary Metals").
- Ltd., as trustee (the "Trustee") under the exchange rights agreement entered into among the Company, ExchangeCo, Callco, and the Trustee (the "Exchange Rights Agreement").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GNPX | Genprex, Inc. | USD 7.81 | ▼ 7.13% |
| CTXR | Citius Pharmaceuticals, Inc. | USD 0.52 | ▼ 7.42% |
| ADIL | Adial Pharmaceuticals, Inc | USD 2.78 | ▲ 2.96% |
| HSDT | Solana Company | USD 1.63 | ▼ 5.78% |
| CHGA | Change Agents Corporation | USD 0.24 | ▼ 13.1% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 14:21 UTC. This page is informational and not investment advice.